Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant.
We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.
Department of Pharmacy, Oregon Health & Science University Hospital and Clinics, Portland, Oregon, USA phaaa@ohsu.edu.
Aaron N
AN
Pham
Department of Pharmacy, Oregon Health & Science University Hospital and Clinics, Portland, Oregon, USA.
Joseph S
JS
Bubalo
Department of Pharmacy, Oregon Health & Science University Hospital and Clinics, Portland, Oregon, USA.
James S
JS
Lewis
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000097:blood; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications / Q000382:microbiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000517:prevention & control*; D012189:Retrospective Studies; D013607:Tablets; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000097:blood*
D000935:Antifungal Agents; D003692:Delayed-Action Preparations; D013607:Tablets; D014230:Triazoles; C101425:posaconazole